The Trump administration’s proposed rule barring drug companies from paying rebates to PBMs and drug plans for Part D Medicare could also affect commercial payers, HHS Secretary Alex Azar said Friday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,